Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 469.70M | 440.10M | 358.74M | 348.81M | 274.08M |
Gross Profit | 446.78M | 97.76M | 83.84M | 92.19M | 72.06M |
EBITDA | 12.33M | 92.74M | 69.90M | 88.94M | 69.50M |
Net Income | -60.70M | 25.04M | 14.60M | 31.27M | 23.03M |
Balance Sheet | |||||
Total Assets | 744.28M | 839.01M | 783.01M | 654.90M | 586.91M |
Cash, Cash Equivalents and Short-Term Investments | 42.44M | 33.85M | 123.19M | 62.20M | 57.97M |
Total Debt | 357.80M | 365.08M | 340.99M | 308.36M | 277.85M |
Total Liabilities | 442.57M | 465.96M | 435.77M | 400.16M | 358.58M |
Stockholders Equity | 301.71M | 373.05M | 347.24M | 254.74M | 228.33M |
Cash Flow | |||||
Free Cash Flow | 42.28M | 27.42M | 9.33M | 49.30M | 28.37M |
Operating Cash Flow | 66.16M | 71.42M | 37.10M | 69.57M | 54.25M |
Investing Cash Flow | -27.90M | -128.96M | -55.69M | -56.66M | -93.53M |
Financing Cash Flow | -29.45M | -31.85M | 81.13M | -7.83M | 75.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | AU$13.82B | 24.55 | 6.86% | 3.83% | 10.15% | 6.20% | |
69 Neutral | AU$553.82M | 18.32 | 18.39% | 4.43% | 7.80% | 99.87% | |
60 Neutral | HK$16.84B | 5.17 | -7.44% | 2.89% | 11.55% | -28.15% | |
55 Neutral | AU$300.02M | ― | -0.87% | 6.62% | 14.24% | -109.59% | |
53 Neutral | AU$1.03B | 113.99 | 1.14% | 2.16% | 7.83% | ― | |
46 Neutral | €559.12M | ― | -4.46% | ― | -7.82% | 98.08% | |
45 Neutral | AU$81.77M | ― | -47.52% | ― | 44.61% | 16.40% |
Integral Diagnostics Limited announced it will hold a group investor conference call on August 26, 2025, following the release of its FY25 results. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and operations.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
Integral Diagnostics Ltd. has been served with a legal claim by the Vendors of the Imaging Queensland business, which it acquired in 2019. The Vendors are seeking damages related to an earn-out valuation dispute, which was previously determined by an independent expert to be $2.2 million. Despite efforts by Integral to resolve the issue based on this valuation, the Vendors have initiated legal proceedings. Integral plans to defend itself in this litigation, which could have implications for its financial provisioning and stakeholder relations.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
Integral Diagnostics (IDX) announced the upcoming retirement of its Managing Director and CEO, Dr. Ian Kadish, effective at the end of FY26. Dr. Kadish has significantly contributed to the company’s growth, transforming it into the second largest radiology provider in Australia and a notable presence in New Zealand. The company is conducting an international search for his successor, aiming for a seamless transition to maintain service standards and capitalize on recent synergies from its merger with Capitol Health.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
Integral Diagnostics announced its participation in the 2025 Macquarie Australia Conference, where it will present its latest developments. This engagement underscores IDX’s commitment to maintaining its leadership position in the medical imaging industry and highlights its ongoing efforts to enhance service quality and patient care.
Challenger Limited has announced that it and its associated entities have ceased to be substantial holders in Integral Diagnostics Limited. This change in holdings may impact Integral Diagnostics’ shareholder composition and influence its market position, as substantial holders often have significant voting power and influence over company decisions.